Eliem Therapeutics to Present at Stifel’s 2022 CNS Days
Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage biotechnology firm, focuses on therapies for neuronal excitability disorders, including chronic pain and epilepsy. On March 29, 2022, Bob Azelby, president and CEO, will present at Stifel’s 2022 CNS Days, starting at 9:30 AM ET. A live webcast will be available on their website, with a replay for 30 days post-event. Eliem aims to develop differentiated product candidates to enhance patient quality of life by restoring neuronal balance in various disorders.
- None.
- None.
SEATTLE and CAMBRIDGE, United Kingdom, March 21, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems, today announced that Bob Azelby, Eliem’s president and chief executive officer, will present at Stifel’s 2022 CNS Days being held virtually on Tuesday, March 29, 2022 at 9:30 AM ET.
A live webcast will be available on the Investors section of the Eliem Therapeutics website at https://www.eliemtx.com. An archived replay will remain available on Eliem’s website for at least 30 days after the conference.
About Eliem Therapeutics, Inc.
Eliem Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems. These disorders often occur when neurons are overly excited or inhibited, leading to an imbalance, and our focus is on restoring homeostasis. We are developing a pipeline of clinically differentiated product candidates focused on validated mechanisms of action with broad therapeutic potential to deliver improved therapeutics for patients with these disorders. Eliem channels its experience, energy, and passion for improving patients’ quality of life to fuel our efforts to develop life-changing novel therapies. At its core, the Eliem team is motivated by the promise of helping patients live happier, more fulfilling lives.
https://eliemtx.com/
Investors
Chris Brinzey
ICR Westwicke
chris.brinzey@westwicke.com
339-970-2843
Media
Marites Coulter
Verge Scientific
Mcoulter@vergescientific.com
415.819.2214
FAQ
What date will Eliem Therapeutics present at Stifel's 2022 CNS Days?
Who is presenting for Eliem Therapeutics at the 2022 CNS Days?
How can I watch the Eliem Therapeutics presentation?
What is the focus of Eliem Therapeutics?
What types of disorders does Eliem Therapeutics address?
